Influence of Aliskiren on Proteinuria

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the proteinuria lowering efficacy as well as tolerability and safety of the renin inhibitor aliskiren compared with that of placebo and angiotensin converting enzyme inhibitor perindopril in patients with non-diabetic chronic renal disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Gdansk
• Treatments: Perindopril

Criteria

Inclusion Criteria:

• age 18-65 years

• chronic non-diabetic proteinuric nephropathy

• creatinine clearance above 30 ml/min

• stable proteinuria above 500 mg/ 24 hours

• blood pressure above 125/75 mmHg and below 150/95 mmHg

• no steroids or other immunosuppressive treatment for a minimum of six months before the study

Exclusion Criteria:

• unstable coronary heart disease

• decompensated congestive heart failure in the previous 6 months

• episode of malignant hypertension or stroke in the history

• diabetes

• creatinine clearance below 30 ml/min